Cargando…

Therapeutic Challenges for Cisplatin-Resistant Ovarian Germ Cell Tumors

The majority of patients with advanced ovarian germ cell cancer are treated by cisplatin-based chemotherapy. Despite adequate first-line treatment, nearly one third of patients relapse and almost half develop cisplatin-resistant disease, which is often fatal. The treatment of cisplatin-resistant dis...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Giorgi, Ugo, Casadei, Chiara, Bergamini, Alice, Attademo, Laura, Cormio, Gennaro, Lorusso, Domenica, Pignata, Sandro, Mangili, Giorgia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6826947/ https://www.ncbi.nlm.nih.gov/pubmed/31627378 http://dx.doi.org/10.3390/cancers11101584

Ejemplares similares

Reproductive Outcomes and Fertility Preservation Strategies in Women with Malignant Ovarian Germ Cell Tumors after Fertility Sparing Surgery
por: Vasta, Francesca Maria, et al.
Publicado: (2020)

Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study
por: Farolfi, Alberto, et al.
Publicado: (2020)

“Intestinal-Type” Vulvar Adenocarcinoma: A Review of the MITO Rare Tumors Group
por: Dellino, Miriam, et al.
Publicado: (2022)

Aggressive Angiomyxoma of the Lower Female Genital Tract in Pregnancy: A Review of the MITO Rare Tumors Group
por: Cicogna, Stefania, et al.
Publicado: (2023)

Radiation Therapy for Gestational Trophoblastic Neoplasia: Forward-Looking Lessons Learnt
por: Barcellini, Amelia, et al.
Publicado: (2023)

Number Needed to Treat in Trials of Targeted Therapies for Advanced Ovarian Cancer
por: Bartoletti, Michele, et al.
Publicado: (2022)

Management of Metastatic Endometrial Cancer: Physicians’ Choices Beyond the First Line. A MITO Survey
por: Giannone, Gaia, et al.
Publicado: (2022)

Management of metastatic endometrial cancer: physicians’ choices beyond the first line after approval of checkpoint inhibitors
por: Arezzo, Francesca, et al.
Publicado: (2023)

How Immunotherapy Modified the Therapeutic Scenario of Endometrial Cancer: A Systematic Review
por: Maiorano, Brigida Anna, et al.
Publicado: (2022)

The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy
por: Maiorano, Brigida Anna, et al.
Publicado: (2022)

Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study
por: Pignata, Sandro, et al.
Publicado: (2008)

Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications
por: Giannone, Gaia, et al.
Publicado: (2019)

Ovarian Cancer Radiosensitivity: What Have We Understood So Far?
por: Barcellini, Amelia, et al.
Publicado: (2022)

Endometriosis-Related Ovarian Cancers: Evidence for a Dichotomy in the Histogenesis of the Two Associated Histotypes
por: Bergamini, Alice, et al.
Publicado: (2023)

Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma
por: Lorusso, Domenica, et al.
Publicado: (2022)

Corrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma
por: Lorusso, Domenica, et al.
Publicado: (2023)

Integration of PARP-inhibitors in ovarian cancer therapy
por: Pietragalla, Antonella, et al.
Publicado: (2020)

Ovarian Cancer: A Landscape of Mitochondria with Emphasis on Mitochondrial Dynamics
por: De Rasmo, Domenico, et al.
Publicado: (2023)

Cisplatin Resistance in Testicular Germ Cell Tumors: Current Challenges from Various Perspectives
por: Lobo, João, et al.
Publicado: (2020)

Clinical Challenges in the Management of Malignant Ovarian Germ Cell Tumours
por: Saani, Iqra, et al.
Publicado: (2023)

Current Evidence on Immunotherapy for Gestational Trophoblastic Neoplasia (GTN)
por: Mangili, Giorgia, et al.
Publicado: (2022)

Locally Performed HRD Testing for Ovarian Cancer? Yes, We Can!
por: Magliacane, Gilda, et al.
Publicado: (2022)

Vulvar Paget’s Disease: A Systematic Review of the MITO Rare Cancer Group
por: Caruso, Giuseppe, et al.
Publicado: (2023)

Clinical outcome of renal cancer patients who early interrupted immunotherapy due to serious immune-related adverse events. Meet-Uro 13 trial on behalf of the MeetUro investigators
por: Stellato, Marco, et al.
Publicado: (2021)

Immune-Related Concepts in Biology and Treatment of Germ-Cell Tumors
por: Chovanec, Michal, et al.
Publicado: (2018)

Napabucasin overcomes cisplatin resistance in ovarian germ cell tumor-derived cell line by inhibiting cancer stemness
por: Schmidtova, Silvia, et al.
Publicado: (2020)

Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy
por: Sirico, Marianna, et al.
Publicado: (2023)

DEAD-Box Helicase 4 (Ddx4)(+) Stem Cells Sustain Tumor Progression in Non-Serous Ovarian Cancers
por: D’Oronzo, Stella, et al.
Publicado: (2020)

Survival in clinical stage I endometrial cancer with single vs. multiple positive pelvic nodes: results of a multi-institutional Italian study
por: Uccella, Stefano, et al.
Publicado: (2018)

Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: Potential treatment options against Testicular Germ Cell Tumors
por: Schepisi, Giuseppe, et al.
Publicado: (2023)

Prognostic Role of Systemic Inflammatory Indexes in Germ Cell Tumors Treated With High-Dose Chemotherapy
por: Cursano, Maria Concetta, et al.
Publicado: (2020)

Impact of Recurrence of Ovarian Cancer on Quality of Life and Outlook for the Future
por: Colombo, Nicoletta, et al.
Publicado: (2017)

Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine
por: Nero, Camilla, et al.
Publicado: (2021)

Severe Complications in Testicular Germ Cell Tumors: The Choriocarcinoma Syndrome
por: Rejlekova, Katarina, et al.
Publicado: (2019)

Primary Mediastinal and Testicular Germ Cell Tumors in Adolescents and Adults: A Comparison of Genomic Alterations and Clinical Implications
por: Urbini, Milena, et al.
Publicado: (2021)

A miRNA signature assessing ovarian cancer prognosis
por: Bagnoli, Marina, et al.
Publicado: (2016)

Molecular Basis of Cisplatin Resistance in Testicular Germ Cell Tumors
por: Bakardjieva-Mihaylova, Violeta, et al.
Publicado: (2019)

Mechanisms of cisplatin sensitivity and resistance in testicular germ cell tumors
por: Singh, Ratnakar, et al.
Publicado: (2019)

Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors
por: Nero, Camilla, et al.
Publicado: (2021)

Contrast-enhanced ultrasound for ovary assessment in a murine model: preliminary findings on the protective role of a gonadotropin-releasing hormone analogue from chemotherapy-induced ovarian damage
por: Venturini, Massimo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ukjmm6t6gdb36go2kj1ses7bgt